Glaukos Stock Forecast, Price & News

+1.55 (+3.13 %)
(As of 07/30/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume605,797 shs
Average Volume959,046 shs
Market Capitalization$2.36 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive GKOS News and Ratings via Email

Sign-up to receive the latest news and ratings for Glaukos and its competitors with MarketBeat's FREE daily newsletter.

Glaukos logo

About Glaukos

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite for use as a standalone procedure in patients with refractory glaucoma; iStent SA, a two-stent product that is designed for use as a standalone glaucoma procedure; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.42 out of 5 stars

Medical Sector

825th out of 2,223 stocks

Surgical & Medical Instruments Industry

82nd out of 185 stocks

Analyst Opinion: 2.9Community Rank: 3.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Glaukos (NYSE:GKOS) Frequently Asked Questions

Is Glaukos a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Glaukos in the last year. There are currently 2 sell ratings and 6 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Glaukos stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GKOS, but not buy additional shares or sell existing shares.
View analyst ratings for Glaukos
or view top-rated stocks.

What stocks does MarketBeat like better than Glaukos?

Wall Street analysts have given Glaukos a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Glaukos wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Glaukos' next earnings date?

Glaukos is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Glaukos

How can I listen to Glaukos' earnings call?

Glaukos will be holding an earnings conference call on Thursday, August 5th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Glaukos' earnings last quarter?

Glaukos Co. (NYSE:GKOS) announced its quarterly earnings results on Wednesday, May, 5th. The medical instruments supplier reported ($0.21) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.30) by $0.09. The medical instruments supplier had revenue of $67.97 million for the quarter, compared to analysts' expectations of $64.82 million. Glaukos had a negative trailing twelve-month return on equity of 6.44% and a negative net margin of 34.83%.
View Glaukos' earnings history

How has Glaukos' stock price been impacted by Coronavirus (COVID-19)?

Glaukos' stock was trading at $38.64 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, GKOS stock has increased by 32.0% and is now trading at $51.00.
View which stocks have been most impacted by COVID-19

What guidance has Glaukos issued on next quarter's earnings?

Glaukos issued an update on its second quarter 2021 earnings guidance on Wednesday, May, 26th. The company provided earnings per share guidance of - for the period. The company issued revenue guidance of $70 million-$72 million, compared to the consensus revenue estimate of $69.56 million.

What price target have analysts set for GKOS?

8 Wall Street analysts have issued 12 month price targets for Glaukos' shares. Their forecasts range from $34.00 to $105.00. On average, they anticipate Glaukos' stock price to reach $63.00 in the next year. This suggests a possible upside of 23.5% from the stock's current price.
View analysts' price targets for Glaukos
or view top-rated stocks among Wall Street analysts.

Who are Glaukos' key executives?

Glaukos' management team includes the following people:
  • Mr. Thomas William Burns, CEO, Pres & Director (Age 60, Pay $1.14M)
  • Mr. Joseph E. Gilliam, CFO & Sr. VP of Corp. Devel. (Age 45, Pay $578.42k)
  • Mr. Chris M. Calcaterra, Chief Operating Officer (Age 61, Pay $553.08k)
  • Dr. Mory Gharib Ph.D., Co-Founder
  • Mr. Christopher William Lewis, Director of Investor Relations, Corp. Strategy & Devel.
  • Ms. Diane W. Biagianti, Sr. VP & Gen. Counsel
  • Ms. Diana A. Scherer, VP of Compliance & Deputy Gen. Counsel
  • Ms. Michele M. Allegretto, Sr. VP of HR
  • Mr. David S. Haffner, Sr. VP of New Technologies
  • Mr. L. Jay Katz M.D., FACS, Chief Medical Officer

What is Thomas W. Burns' approval rating as Glaukos' CEO?

10 employees have rated Glaukos CEO Thomas W. Burns on Glassdoor.com. Thomas W. Burns has an approval rating of 100% among Glaukos' employees. This puts Thomas W. Burns in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Glaukos' key competitors?

What other stocks do shareholders of Glaukos own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Glaukos investors own include NVIDIA (NVDA), Marvell Technology (MRVL), PTC Therapeutics (PTCT), PayPal (PYPL), QUALCOMM (QCOM), Alibaba Group (BABA), Teladoc Health (TDOC), Intel (INTC), Advanced Micro Devices (AMD) and The Boeing (BA).

When did Glaukos IPO?

(GKOS) raised $76 million in an initial public offering on Thursday, June 25th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs served as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers.

What is Glaukos' stock symbol?

Glaukos trades on the New York Stock Exchange (NYSE) under the ticker symbol "GKOS."

Who are Glaukos' major shareholders?

Glaukos' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Alliancebernstein L.P. (0.15%), Taylor Frigon Capital Management LLC (0.15%) and State of Alaska Department of Revenue (0.07%). Company insiders that own Glaukos stock include Joseph E Gilliam, Thomas William Burns and William J Phd Link.
View institutional ownership trends for Glaukos

Which major investors are selling Glaukos stock?

GKOS stock was sold by a variety of institutional investors in the last quarter, including Taylor Frigon Capital Management LLC. Company insiders that have sold Glaukos company stock in the last year include Joseph E Gilliam, and William J Phd Link.
View insider buying and selling activity for Glaukos
or view top insider-selling stocks.

Which major investors are buying Glaukos stock?

GKOS stock was purchased by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., and State of Alaska Department of Revenue.
View insider buying and selling activity for Glaukos
or or view top insider-buying stocks.

How do I buy shares of Glaukos?

Shares of GKOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Glaukos' stock price today?

One share of GKOS stock can currently be purchased for approximately $51.00.

How much money does Glaukos make?

Glaukos has a market capitalization of $2.36 billion and generates $224.96 million in revenue each year. The medical instruments supplier earns $-120,350,000.00 in net income (profit) each year or ($1.15) on an earnings per share basis.

How many employees does Glaukos have?

Glaukos employs 653 workers across the globe.

What is Glaukos' official website?

The official website for Glaukos is www.glaukos.com.

Where are Glaukos' headquarters?

Glaukos is headquartered at 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672.

How can I contact Glaukos?

Glaukos' mailing address is 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672. The medical instruments supplier can be reached via phone at 949-367-9600 or via email at [email protected]

This page was last updated on 7/31/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.